107 related articles for article (PubMed ID: 10333714)
61. The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer.
Helmy A; Hammam OA; El Lithy TR; El Deen Wishahi MM
MedGenMed; 2007 Nov; 9(4):34. PubMed ID: 18311384
[TBL] [Abstract][Full Text] [Related]
62. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder.
Chang S; Lee S; Lee C; Kim JI; Kim Y
Urology; 2000 Mar; 55(3):448-52. PubMed ID: 10699635
[TBL] [Abstract][Full Text] [Related]
63. Bladder wash cytology and flow cytometry for the diagnosis of transitional cell carcinoma of the urinary bladder.
Romero J; Alos L; Mallofre C; Sole M; Gutierrez R; Alcover J; Carretero P
Eur Urol; 1992; 21 Suppl 1():13-5. PubMed ID: 1425832
[TBL] [Abstract][Full Text] [Related]
64. Association of Cytokeratin and Vimentin Protein in the Genesis of Transitional Cell Carcinoma of Urinary Bladder Patients.
Rahmani AH; Babiker AY; AlWanian WM; Elsiddig SA; Faragalla HE; Aly SM
Dis Markers; 2015; 2015():204759. PubMed ID: 26640315
[TBL] [Abstract][Full Text] [Related]
65. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder.
Basakci A; Kirkali Z; Tuzel E; Yorukoglu K; Mungan MU; Sade M
Eur Urol; 2002 Mar; 41(3):342-5. PubMed ID: 12180239
[TBL] [Abstract][Full Text] [Related]
66. Oncoprotein changes in the flat lesions with atypia and invasive neoplasms of the urinary bladder.
Kee KH; Lee MJ; Ro JY
Oncol Rep; 2001; 8(3):579-83. PubMed ID: 11295084
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer.
Ravery V; Grignon D; Angulo J; Pontes E; Montie J; Crissman J; Chopin D
Urol Res; 1997; 25(1):9-17. PubMed ID: 9079740
[TBL] [Abstract][Full Text] [Related]
68. Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma.
Coombs LM; Pigott DA; Eydmann ME; Proctor AJ; Knowles MA
Br J Cancer; 1993 Mar; 67(3):578-84. PubMed ID: 8439507
[TBL] [Abstract][Full Text] [Related]
69. Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines.
Iwamura M; Ishibe M; Sluss PM; Cockett AT
Urol Res; 1993 Jan; 21(1):27-32. PubMed ID: 8456535
[TBL] [Abstract][Full Text] [Related]
70. Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma.
Walters L; Martin O; Price J; Sula MM
Vet Comp Oncol; 2018 Mar; 16(1):E117-E122. PubMed ID: 28884928
[TBL] [Abstract][Full Text] [Related]
71. Peanut lectin binding sites in transitional cell carcinoma of the urinary bladder.
Lehman TP; Cooper HS; Mulholland SG
Cancer; 1984 Jan; 53(2):272-7. PubMed ID: 6360337
[TBL] [Abstract][Full Text] [Related]
72. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Hammam OA; Aziz AA; Roshdy MS; Abdel Hadi AM
Medscape J Med; 2008 Mar; 10(3):60. PubMed ID: 18449376
[TBL] [Abstract][Full Text] [Related]
73. Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder.
Abdollahzadeh P; Madani SH; Khazaei S; Sajadimajd S; Izadi B; Najafi F
Urol J; 2017 Nov; 14(6):5047-5050. PubMed ID: 29101759
[TBL] [Abstract][Full Text] [Related]
74. Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma.
Rossel M; Billerey C; Bittard H; Ksiazek P; Alber D; Revillard JP; Vuitton DA
Urol Res; 1991; 19(6):361-6. PubMed ID: 1759330
[TBL] [Abstract][Full Text] [Related]
75. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma.
Ravery V; Jouanneau J; Gil Diez S; Abbou CC; Caruelle JP; Barritault D; Chopin DK
Urol Res; 1992; 20(3):211-4. PubMed ID: 1377428
[TBL] [Abstract][Full Text] [Related]
76. Changes in expression of TLR-4, TGF-β, INF-γ, TNF-α in cultured T24/83 cells of invasive bladder cancer treated with cisplatin and/or polyphenolic adjuvant melanin.
Yakovlev PG; Gorbach OI; Khranovska NM; Beliayeva AV; Skachkova OV; Skaterna TD; Kalachniuk LG; Ostapchenko LI; Garmanchuk LV
Exp Oncol; 2021 Mar; 43(1):7-14. PubMed ID: 33785718
[TBL] [Abstract][Full Text] [Related]
77. Protein kinase C (PKC) isoenzymes immunohistochemistry in lymph node revealing solution-fixed, paraffin-embedded bladder tumors.
Koren R; Langzam L; Paz A; Livne PM; Gal R; Sampson SR
Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):166-71. PubMed ID: 10937066
[TBL] [Abstract][Full Text] [Related]
78. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.
Feldman AS; Banyard J; Wu CL; McDougal WS; Zetter BR
Clin Cancer Res; 2009 Feb; 15(3):1024-31. PubMed ID: 19188175
[TBL] [Abstract][Full Text] [Related]
79. Transitional cell carcinoma express vitamin D receptors.
Hermann GG; Andersen CB
Scand J Urol Nephrol; 1997 Apr; 31(2):161-6. PubMed ID: 9165580
[TBL] [Abstract][Full Text] [Related]
80. A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder.
Eschwège P; Ferlicot S; Droupy S; Ba N; Conti M; Loric S; Coindard G; Denis I; Ferretti L; Cornelius A; Legrand A; Bedossa P; Benoît G; Jardin A; Scardino P
Eur Urol; 2003 Oct; 44(4):435-41. PubMed ID: 14499677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
